Boston Therapeutics Appoints Zbigniew J. Witczak, Ph.D., to

MANCHESTER, NH--(Marketwired - Jul 29, 2014) - Boston Therapeutics, Inc. ( OTCQB : BTHE ), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Zbigniew J. Witczak, Ph.D. to its Scientific Advisory Board (SAB). This brings the total number of Scientific Advisory Board members to six.

Dr. Witczak is professor and chair of the Department of Pharmaceutical Sciences at Wilkes University in Wilkes-Barre, Pennsylvania, and has taught Principles of Bioorganic and Medicinal Chemistry at the Nesbitt School of Pharmacy at Wilkes University for the past 14 years. A member of the American Chemical Society, he is the recipient of numerous honors and awards, including Selected 2011 ACS Fellow of the American Chemical Society and Elected U.S. Representative to the International Carbohydrate Organization in 2006. He is the author or coauthor of more than 75 research articles in the area of carbohydrate chemistry. He received Ph.D. and M.S. degrees in organic chemistry from Medical University in Lódz, Poland.

Dr. Witczak said, "The need for innovative treatments in diabetes has never been greater, in light of the increasing numbers of Americans with this disease. I believe Boston Therapeutics is doing valuable and innovative work in this area, and I am looking forward to helping guide the Company's development of its diabetes-related treatments."

Rom E. Eliaz, Ph.D., MBA, chair of the Boston Therapeutics' Scientific Advisory Board and member of the Company's Board of Directors, said, "The appointment of Dr. Witczak to the Board brings Boston Therapeutics an additional distinguished expert who will provide unique expertise to help guide the Company through its future endeavors."

David Platt, Chief Executive Officer of Boston Therapeutics, said, "We are extremely fortunate to have attracted Dr. Witczak to serve on our Scientific Advisory Board. We believe his decades of research experience will be a significant asset to us as we continue to seek the best path forward to helping those with diabetes."

Other members of the SAB include Larry K. Ellingson, former chair of the American Diabetes Association and chair of the Company's Medical Advisory Board; David Platt, Ph.D., the Company's CEO; Ben Rivnay, Ph.D., the Company's Chief Scientist; and Dale H. Conaway, D.V.M., and Henry J. Esber, Ph.D., both of whom are members of the Company's Board of Directors.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a new generation of Alpha Glucosidase Inhibitor, is a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation. The Company is currently enrolling patients in a Phase llb clinical study with BTI-320 in patients with type 2 diabetes. IPOXYN is an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes and is pre-clinical. The company produces and sells SUGARDOWN ^® , a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com .

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.